Bruker Corporation (BRKR) exhibits 45.9% gross margins and 1.3% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 75.7x enterprise multiple and 4.8% implied options volatility.
Sustained 45.9% gross profitability converts into 2.0% operating margin and 1.3% ROIC, outpacing sector cost of capital.
ROIC: 1.3% // GM: 45.9%YoY revenue trajectory of +2.1% paired with 0.46% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +2.1% // FCF YLD: 0.46%Altman Z-Score of 2.81 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.81 // F-SCORE: 6/9Trading at 24.0x trailing P/E (22.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 75.7xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $55.69 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend -0.2% net margins.
NET MARGIN: -0.2% // D/E: 0.75x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BRKR & activate live FRED threshold breach alerts.